Members log in

Remember me

Do not refresh my screen on timeout

close

News

ACCEA 2018: Deadline for applications for ABN and RCP support is Wednesday 28 February 2018.

Read More

Events

ABN Annual Meeting Birmingham 2018 9 - 11 May 2018. Premeeting day 8 May 2018

Read More

ABN statement on use of sodium valproate in pregnancy for general readers

The Association of British Neurologists has been concerned for many years about women taking the epilepsy treatment sodium valproate in pregnancy.  We strongly support the proposed changes in labeling and the provision of additional information for women taking this treatment. Valproate can damage the unborn baby, and can increase the risk of low intelligence and autism in children whose mothers took this medication in pregnancy.

 However, for women taking valproate and thinking of a pregnancy, changing to another treatment is not straightforward, because valproate is such a good treatment for some kinds of epilepsy. If a young woman is already taking valproate and would like to become pregnant, it is important she is made aware of and understands the other risks.

 Thus, we are very keen that any woman who is taking valproate must know all about the risks of becoming pregnant whilst taking this treatment. However, we also know changing to another treatment can have its own problems, and anyone making this change will need a lot of information and support.

 

A more detailed statement is available here

 

Click here for the full document

News

ACCEA 2018: Deadline for applications for ABN and RCP support is Wednesday 28 February 2018.

Read More

Events

ABN Annual Meeting Birmingham 2018 9 - 11 May 2018. Premeeting day 8 May 2018

Read More